In-Depth Examination Of 4 Analyst Recommendations For Teva Pharmaceutical Indus
Portfolio Pulse from Benzinga Insights
Teva Pharmaceutical Indus (NYSE:TEVA) received mixed analyst ratings over the last quarter, with 3 bullish and 1 indifferent rating. The average 12-month price target is $13.0, up from the previous $9.67, with a high estimate of $14.00 and a low of $12.00. Analysts from Jefferies, Piper Sandler, HSBC, and UBS have adjusted their price targets and ratings, reflecting a positive outlook on the company's performance. Despite this, Teva's financial indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management show mixed results compared to industry averages.
January 23, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva Pharmaceutical received updated analyst ratings with a higher average price target of $13.0, indicating a positive sentiment among analysts. Financial metrics show a mixed performance, with solid revenue growth but concerns over profitability and debt management.
The increase in the average price target and positive ratings from analysts suggest a bullish sentiment, which could lead to a short-term positive impact on TEVA's stock price. However, the mixed financial indicators may temper the stock's performance, hence the importance score is not at the maximum. The confidence level is at 75 due to the inherent uncertainty in analyst predictions and market reactions.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100